The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna noted that the new shot, dubbed mRNA-1010, hit the highest efficacy target that it set for the trial, which included nearly 41,000 people aged 50 and above.

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.